Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Overlap between age-at-onset and disease-progression determinants in Huntington disease.

Aziz NA, van der Burg JMM, Tabrizi SJ, Landwehrmeyer GB.

Neurology. 2018 Jun 12;90(24):e2099-e2106. doi: 10.1212/WNL.0000000000005690. Epub 2018 May 9.

2.

Objective assessment of gait and posture in premanifest and manifest Huntington disease - A multi-center study.

Beckmann H, Bohlen S, Saft C, Hoffmann R, Gerss J, Muratori L, Ringelstein EB, Landwehrmeyer GB, Reilmann R.

Gait Posture. 2018 May;62:451-457. doi: 10.1016/j.gaitpost.2018.03.039. Epub 2018 Apr 7.

PMID:
29660633
3.

The contribution of gender differences in motor, behavioral and cognitive features to functional capacity, independence and quality of life in patients with Huntington's disease.

Zielonka D, Ren M, De Michele G, Roos RAC, Squitieri F, Bentivoglio AR, Marcinkowski JT, Landwehrmeyer GB.

Parkinsonism Relat Disord. 2018 Apr;49:42-47. doi: 10.1016/j.parkreldis.2018.01.006. Epub 2018 Jan 5.

PMID:
29326033
4.

Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression.

Steinacker P, Verde F, Fang L, Feneberg E, Oeckl P, Roeber S, Anderl-Straub S, Danek A, Diehl-Schmid J, Fassbender K, Fliessbach K, Foerstl H, Giese A, Jahn H, Kassubek J, Kornhuber J, Landwehrmeyer GB, Lauer M, Pinkhardt EH, Prudlo J, Rosenbohm A, Schneider A, Schroeter ML, Tumani H, von Arnim CAF, Weishaupt J, Weydt P, Ludolph AC, Yilmazer Hanke D, Otto M; FTLDc study group.

J Neurol Neurosurg Psychiatry. 2018 Mar;89(3):239-247. doi: 10.1136/jnnp-2017-317138. Epub 2017 Nov 15.

PMID:
29142138
5.

Body weight is a robust predictor of clinical progression in Huntington disease.

van der Burg JMM, Gardiner SL, Ludolph AC, Landwehrmeyer GB, Roos RAC, Aziz NA.

Ann Neurol. 2017 Sep;82(3):479-483. doi: 10.1002/ana.25007. Epub 2017 Aug 22.

PMID:
28779551
6.

High-resolution respirometry of fine-needle muscle biopsies in pre-manifest Huntington's disease expansion mutation carriers shows normal mitochondrial respiratory function.

Buck E, Zügel M, Schumann U, Merz T, Gumpp AM, Witting A, Steinacker JM, Landwehrmeyer GB, Weydt P, Calzia E, Lindenberg KS.

PLoS One. 2017 Apr 13;12(4):e0175248. doi: 10.1371/journal.pone.0175248. eCollection 2017.

7.

Intact sensory-motor network structure and function in far from onset premanifest Huntington's disease.

Gorges M, Müller HP, Mayer IM, Grupe GS, Kammer T, Grön G, Kassubek J, Landwehrmeyer GB, Wolf RC, Orth M.

Sci Rep. 2017 Mar 7;7:43841. doi: 10.1038/srep43841.

8.

Identification of extreme motor phenotypes in Huntington's disease.

Braisch U, Hay B, Muche R, Rothenbacher D, Landwehrmeyer GB, Long JD, Orth M; REGISTRY Investigators of the European Huntington's Disease Network and COHORT Investigators of the Huntington Study Group.

Am J Med Genet B Neuropsychiatr Genet. 2017 Apr;174(3):283-294. doi: 10.1002/ajmg.b.32514. Epub 2016 Nov 21.

PMID:
27868347
9.

The neuropsychology of first impressions: Evidence from Huntington's disease.

Sprengelmeyer R, Young AW, Baldas EM, Ratheiser I, Sutherland CAM, Müller HP, Grön G, Süssmuth SD, Landwehrmeyer GB, Orth M.

Cortex. 2016 Dec;85:100-115. doi: 10.1016/j.cortex.2016.10.006. Epub 2016 Oct 21.

PMID:
27852003
10.

Fast-to-Slow Transition of Skeletal Muscle Contractile Function and Corresponding Changes in Myosin Heavy and Light Chain Formation in the R6/2 Mouse Model of Huntington's Disease.

Hering T, Braubach P, Landwehrmeyer GB, Lindenberg KS, Melzer W.

PLoS One. 2016 Nov 7;11(11):e0166106. doi: 10.1371/journal.pone.0166106. eCollection 2016.

11.

Corrigendum to "Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's disease" [Parkinsonism Relat. Disord. 25C (2016) 58-64].

Martinez-Horta S, Perez-Perez J, van Duijn E, Fernandez-Bobadilla R, Carceller M, Pagonabarraga J, Pascual-Sedano B, Campolongo A, Ruiz-Idiago J, Sampedro F, Landwehrmeyer GB; Spanish REGISTRY investigators of the European Huntington's Disease Network, Kulisevsky J.

Parkinsonism Relat Disord. 2016 Oct;31:161. doi: 10.1016/j.parkreldis.2016.08.011. Epub 2016 Aug 25. No abstract available.

PMID:
27567724
12.

Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease.

Martinez-Horta S, Perez-Perez J, van Duijn E, Fernandez-Bobadilla R, Carceller M, Pagonabarraga J, Pascual-Sedano B, Campolongo A, Ruiz-Idiago J, Sampedro F, Landwehrmeyer GB; Spanish REGISTRY investigators of the European Huntington's Disease Network, Kulisevsky J.

Parkinsonism Relat Disord. 2016 Apr;25:58-64. doi: 10.1016/j.parkreldis.2016.02.008. Epub 2016 Feb 11. Erratum in: Parkinsonism Relat Disord. 2016 Oct;31:161.

PMID:
26898966
13.

Medication Use in Early-HD Participants in Track-HD: an Investigation of its Effects on Clinical Performance.

Keogh R, Frost C, Owen G, Daniel RM, Langbehn DR, Leavitt B, Durr A, Roos RA, Landwehrmeyer GB, Reilmann R, Borowsky B, Stout J, Craufurd D, Tabrizi SJ.

PLoS Curr. 2016 Jan 11;8. pii: ecurrents.hd.8060298fac1801b01ccea6acc00f97cb. doi: 10.1371/currents.hd.8060298fac1801b01ccea6acc00f97cb.

14.

Motor network structure and function are associated with motor performance in Huntington's disease.

Müller HP, Gorges M, Grön G, Kassubek J, Landwehrmeyer GB, Süßmuth SD, Wolf RC, Orth M.

J Neurol. 2016 Mar;263(3):539-49. doi: 10.1007/s00415-015-8014-y. Epub 2016 Jan 13.

PMID:
26762394
15.

Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study.

Klöppel S, Gregory S, Scheller E, Minkova L, Razi A, Durr A, Roos RA, Leavitt BR, Papoutsi M, Landwehrmeyer GB, Reilmann R, Borowsky B, Johnson H, Mills JA, Owen G, Stout J, Scahill RI, Long JD, Rees G, Tabrizi SJ; Track-On investigators.

EBioMedicine. 2015 Aug 4;2(10):1420-9. doi: 10.1016/j.ebiom.2015.08.002. eCollection 2015 Oct.

16.

Fat-free mass and its predictors in Huntington's disease.

Süssmuth SD, Müller VM, Geitner C, Landwehrmeyer GB, Iff S, Gemperli A, Orth M.

J Neurol. 2015 Jun;262(6):1533-40. doi: 10.1007/s00415-015-7753-0. Epub 2015 Apr 23.

PMID:
25904208
17.

A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease.

Reilmann R, Rouzade-Dominguez ML, Saft C, Süssmuth SD, Priller J, Rosser A, Rickards H, Schöls L, Pezous N, Gasparini F, Johns D, Landwehrmeyer GB, Gomez-Mancilla B.

Mov Disord. 2015 Mar;30(3):427-31. doi: 10.1002/mds.26174. Epub 2015 Feb 17.

PMID:
25689146
18.

Abnormal cerebellar volume and corticocerebellar dysfunction in early manifest Huntington's disease.

Wolf RC, Thomann PA, Sambataro F, Wolf ND, Vasic N, Landwehrmeyer GB, Süßmuth SD, Orth M.

J Neurol. 2015;262(4):859-69. doi: 10.1007/s00415-015-7642-6. Epub 2015 Jan 28.

PMID:
25626721
19.

Update on Huntington's disease: advances in care and emerging therapeutic options.

Zielonka D, Mielcarek M, Landwehrmeyer GB.

Parkinsonism Relat Disord. 2015 Mar;21(3):169-78. doi: 10.1016/j.parkreldis.2014.12.013. Epub 2014 Dec 19. Review.

PMID:
25572500
20.

Altered Ca(2+) signaling in skeletal muscle fibers of the R6/2 mouse, a model of Huntington's disease.

Braubach P, Orynbayev M, Andronache Z, Hering T, Landwehrmeyer GB, Lindenberg KS, Melzer W.

J Gen Physiol. 2014 Nov;144(5):393-413. doi: 10.1085/jgp.201411255.

21.

An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease.

Süssmuth SD, Haider S, Landwehrmeyer GB, Farmer R, Frost C, Tripepi G, Andersen CA, Di Bacco M, Lamanna C, Diodato E, Massai L, Diamanti D, Mori E, Magnoni L, Dreyhaupt J, Schiefele K, Craufurd D, Saft C, Rudzinska M, Ryglewicz D, Orth M, Brzozy S, Baran A, Pollio G, Andre R, Tabrizi SJ, Darpo B, Westerberg G; PADDINGTON Consortium.

Br J Clin Pharmacol. 2015 Mar;79(3):465-76. doi: 10.1111/bcp.12512.

22.

Impact of the control for corrupted diffusion tensor imaging data in comparisons at the group level: an application in Huntington disease.

Müller HP, Kassubek J, Grön G, Sprengelmeyer R, Ludolph AC, Klöppel S, Hobbs NZ, Roos RA, Duerr A, Tabrizi SJ, Orth M, Süssmuth SD, Landwehrmeyer GB.

Biomed Eng Online. 2014 Sep 1;13:128. doi: 10.1186/1475-925X-13-128.

23.

Two-point magnitude MRI for rapid mapping of brown adipose tissue and its application to the R6/2 mouse model of Huntington disease.

Lindenberg KS, Weydt P, Müller HP, Bornstedt A, Ludolph AC, Landwehrmeyer GB, Rottbauer W, Kassubek J, Rasche V.

PLoS One. 2014 Aug 21;9(8):e105556. doi: 10.1371/journal.pone.0105556. eCollection 2014.

24.

Abnormal resting-state connectivity of motor and cognitive networks in early manifest Huntington's disease.

Wolf RC, Sambataro F, Vasic N, Depping MS, Thomann PA, Landwehrmeyer GB, Süssmuth SD, Orth M.

Psychol Med. 2014 Nov;44(15):3341-56. doi: 10.1017/S0033291714000579. Epub 2014 Mar 27.

PMID:
25066491
25.

Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY).

van Duijn E, Craufurd D, Hubers AA, Giltay EJ, Bonelli R, Rickards H, Anderson KE, van Walsem MR, van der Mast RC, Orth M, Landwehrmeyer GB; European Huntington's Disease Network Behavioural Phenotype Working Group.

J Neurol Neurosurg Psychiatry. 2014 Dec;85(12):1411-8. doi: 10.1136/jnnp-2013-307343. Epub 2014 May 14.

PMID:
24828898
26.

A single nucleotide polymorphism in the coding region of PGC-1α is a male-specific modifier of Huntington disease age-at-onset in a large European cohort.

Weydt P, Soyal SM, Landwehrmeyer GB, Patsch W; European Huntington Disease Network.

BMC Neurol. 2014 Jan 2;14:1. doi: 10.1186/1471-2377-14-1.

27.

Evaluating multicenter DTI data in Huntington's disease on site specific effects: An ex post facto approach.

Müller HP, Grön G, Sprengelmeyer R, Kassubek J, Ludolph AC, Hobbs N, Cole J, Roos RA, Duerr A, Tabrizi SJ, Landwehrmeyer GB, Süssmuth SD.

Neuroimage Clin. 2013 Jan 3;2:161-7. doi: 10.1016/j.nicl.2012.12.005. eCollection 2013.

28.

The neuroanatomy of subthreshold depressive symptoms in Huntington's disease: a combined diffusion tensor imaging (DTI) and voxel-based morphometry (VBM) study.

Sprengelmeyer R, Orth M, Müller HP, Wolf RC, Grön G, Depping MS, Kassubek J, Justo D, Rees EM, Haider S, Cole JH, Hobbs NZ, Roos RA, Dürr A, Tabrizi SJ, Süssmuth SD, Landwehrmeyer GB.

Psychol Med. 2014 Jul;44(9):1867-78. doi: 10.1017/S003329171300247X. Epub 2013 Oct 7.

PMID:
24093462
29.

Longitudinal task-negative network analyses in preclinical Huntington's disease.

Wolf RC, Sambataro F, Vasic N, Wolf ND, Thomann PA, Landwehrmeyer GB, Orth M.

Eur Arch Psychiatry Clin Neurosci. 2014 Sep;264(6):493-505. doi: 10.1007/s00406-013-0447-7. Epub 2013 Sep 27.

PMID:
24071913
30.

The influence of gender on phenotype and disease progression in patients with Huntington's disease.

Zielonka D, Marinus J, Roos RA, De Michele G, Di Donato S, Putter H, Marcinkowski J, Squitieri F, Bentivoglio AR, Landwehrmeyer GB.

Parkinsonism Relat Disord. 2013 Feb;19(2):192-7. doi: 10.1016/j.parkreldis.2012.09.012. Epub 2012 Oct 25.

PMID:
23102616
31.

Brain structure in preclinical Huntington's disease: a multi-method approach.

Wolf RC, Thomann PA, Thomann AK, Vasic N, Wolf ND, Landwehrmeyer GB, Orth M.

Neurodegener Dis. 2013;12(1):13-22. doi: 10.1159/000338635. Epub 2012 Aug 17.

PMID:
22906775
32.

Brain activation and functional connectivity in premanifest Huntington's disease during states of intrinsic and phasic alertness.

Wolf RC, Grön G, Sambataro F, Vasic N, Wolf ND, Thomann PA, Saft C, Landwehrmeyer GB, Orth M.

Hum Brain Mapp. 2012 Sep;33(9):2161-73. doi: 10.1002/hbm.21348. Epub 2011 Aug 25.

PMID:
22887827
33.

TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease.

Lee JH, Lee JM, Ramos EM, Gillis T, Mysore JS, Kishikawa S, Hadzi T, Hendricks AE, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Squitieri F, Gellera C, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Sequeiros J, Landwehrmeyer GB; Registry Study of the European Huntington's Disease Network, Shoulson I; Huntington Study Group COHORT project, Myers RH, MacDonald ME, Gusella JF.

Biochem Biophys Res Commun. 2012 Aug 3;424(3):404-8. Epub 2012 Jul 3.

34.

Default-mode network changes in preclinical Huntington's disease.

Wolf RC, Sambataro F, Vasic N, Wolf ND, Thomann PA, Saft C, Landwehrmeyer GB, Orth M.

Exp Neurol. 2012 Sep;237(1):191-8. doi: 10.1016/j.expneurol.2012.06.014. Epub 2012 Jun 25.

PMID:
22742947
35.

A greatly extended PPARGC1A genomic locus encodes several new brain-specific isoforms and influences Huntington disease age of onset.

Soyal SM, Felder TK, Auer S, Hahne P, Oberkofler H, Witting A, Paulmichl M, Landwehrmeyer GB, Weydt P, Patsch W; European Huntington Disease Network.

Hum Mol Genet. 2012 Aug 1;21(15):3461-73. doi: 10.1093/hmg/dds177. Epub 2012 May 15.

PMID:
22589246
36.

Current Pharmacological Management in Juvenile Huntington's Disease.

Robertson L, Santini H, O'Donovan KL, Squitieri F, Barker RA, Rakowicz M, Landwehrmeyer GB, Quarrell O.

Version 3. PLoS Curr. 2012 Feb 15 [revised 2012 Jan 1];4:RRN1304.

37.

CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion.

Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR, Warby SC, Morrison P, Nance M, Ross CA, Margolis RL, Squitieri F, Orobello S, Di Donato S, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Sequeiros J, Paulsen JS; PREDICT-HD study of the Huntington Study Group (HSG), Landwehrmeyer GB; REGISTRY study of the European Huntington's Disease Network, Myers RH; HD-MAPS Study Group, MacDonald ME, Gusella JF; COHORT study of the HSG.

Neurology. 2012 Mar 6;78(10):690-5. doi: 10.1212/WNL.0b013e318249f683. Epub 2012 Feb 8.

38.

Stability effects on results of diffusion tensor imaging analysis by reduction of the number of gradient directions due to motion artifacts: an application to presymptomatic Huntington's disease.

Müller HP, Süssmuth SD, Landwehrmeyer GB, Ludolph A, Tabrizi SJ, Kloppel S, Kassubek J.

Version 2. PLoS Curr. 2011 Dec 12 [revised 2012 Jan 1];3:RRN1292.

39.

NMDA receptor gene variations as modifiers in Huntington disease: a replication study.

Saft C, Epplen JT, Wieczorek S, Landwehrmeyer GB, Roos RA, de Yebenes JG, Dose M, Tabrizi SJ, Craufurd D; REGISTRY Investigators of the European Huntington's Disease Network, Arning L.

PLoS Curr. 2011 Oct 4;3:RRN1247. doi: 10.1371/currents.RRN1247.

40.

Discrepancies in reporting the CAG repeat lengths for Huntington's disease.

Quarrell OW, Handley O, O'Donovan K, Dumoulin C, Ramos-Arroyo M, Biunno I, Bauer P, Kline M, Landwehrmeyer GB; European Huntington’s Disease Network.

Eur J Hum Genet. 2012 Jan;20(1):20-6. doi: 10.1038/ejhg.2011.136. Epub 2011 Aug 3.

41.

Assessment of motor symptoms and functional impact in prodromal and early huntington disease.

Vaccarino AL, Sills T, Anderson KE, Biglan K, Borowsky B, Giuliano J, Guttman M, Ho AK, Kennard C, Kupchak P, Landwehrmeyer GB, Michell A, Paulsen JS, Reilmann R, van Kammen DP, Warner JH, Evans K.

Version 2. PLoS Curr. 2011 Jun 14 [revised 2011 Jan 1];2:RRN1244.

42.

Longitudinal functional magnetic resonance imaging of cognition in preclinical Huntington's disease.

Wolf RC, Sambataro F, Vasic N, Wolf ND, Thomann PA, Landwehrmeyer GB, Orth M.

Exp Neurol. 2011 Oct;231(2):214-22. doi: 10.1016/j.expneurol.2011.06.011. Epub 2011 Jun 25.

PMID:
21726553
43.

Fully automated atlas-based MR imaging volumetry in Huntington disease, compared with manual volumetry.

Kassubek J, Pinkhardt EH, Dietmaier A, Ludolph AC, Landwehrmeyer GB, Huppertz HJ.

AJNR Am J Neuroradiol. 2011 Aug;32(7):1328-32. doi: 10.3174/ajnr.A2514. Epub 2011 Jun 16.

44.

Magnetic resonance perfusion imaging of resting-state cerebral blood flow in preclinical Huntington's disease.

Wolf RC, Grön G, Sambataro F, Vasic N, Wolf ND, Thomann PA, Saft C, Landwehrmeyer GB, Orth M.

J Cereb Blood Flow Metab. 2011 Sep;31(9):1908-18. doi: 10.1038/jcbfm.2011.60. Epub 2011 May 11.

45.

Utilisation of Healthcare and Associated Services in Huntington's disease: a data mining study.

Busse M, Al-Madfai DH, Kenkre J, Landwehrmeyer GB, Bentivoglio A, Rosser A; European Huntington's Disease Network.

PLoS Curr. 2011 Jan 21;3:RRN1206. doi: 10.1371/currents.RRN1206.

46.

Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis.

Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R, Stout JC; TRACK-HD Investigators.

Lancet Neurol. 2011 Jan;10(1):31-42. doi: 10.1016/S1474-4422(10)70276-3. Epub 2010 Dec 2.

PMID:
21130037
47.

Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY.

Orth M; European Huntington's Disease Network, Handley OJ, Schwenke C, Dunnett S, Wild EJ, Tabrizi SJ, Landwehrmeyer GB.

J Neurol Neurosurg Psychiatry. 2011 Dec;82(12):1409-12. doi: 10.1136/jnnp.2010.209668. Epub 2010 Nov 19. No abstract available.

PMID:
21097549
48.

Tapping linked to function and structure in premanifest and symptomatic Huntington disease.

Bechtel N, Scahill RI, Rosas HD, Acharya T, van den Bogaard SJ, Jauffret C, Say MJ, Sturrock A, Johnson H, Onorato CE, Salat DH, Durr A, Leavitt BR, Roos RA, Landwehrmeyer GB, Langbehn DR, Stout JC, Tabrizi SJ, Reilmann R.

Neurology. 2010 Dec 14;75(24):2150-60. doi: 10.1212/WNL.0b013e3182020123. Epub 2010 Nov 10.

49.

Observing Huntington's Disease: the European Huntington's Disease Network's REGISTRY.

Orth M, Handley OJ, Schwenke C, Dunnett SB, Craufurd D, Ho AK, Wild E, Tabrizi SJ, Landwehrmeyer GB; Investigators of the European Huntington's Disease Network.

Version 2. PLoS Curr. 2010 Sep 28 [revised 2011 Jan 1];2:RRN1184.

50.

Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes.

Maier C, Baron R, Tölle TR, Binder A, Birbaumer N, Birklein F, Gierthmühlen J, Flor H, Geber C, Huge V, Krumova EK, Landwehrmeyer GB, Magerl W, Maihöfner C, Richter H, Rolke R, Scherens A, Schwarz A, Sommer C, Tronnier V, Uçeyler N, Valet M, Wasner G, Treede RD.

Pain. 2010 Sep;150(3):439-50. doi: 10.1016/j.pain.2010.05.002.

PMID:
20627413

Supplemental Content

Loading ...
Support Center